Last reviewed · How we verify
VA Greater Los Angeles Healthcare System — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Low Volume iso-osmolar non-ionic radio contrast medium | Low Volume iso-osmolar non-ionic radio contrast medium | marketed | ||||
| Acetylcysteine Inhalation | Acetylcysteine Inhalation | marketed | ||||
| Sodium Bicarbonate Solution | Sodium Bicarbonate Solution | marketed | Alkalinizing agent | General/Supportive Care |
Therapeutic area mix
- General/Supportive Care · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Hospital General "Dr. Miguel Silva" de Morelia · 1 shared drug class
- Jennifer Gassman, PhD · 1 shared drug class
- The Western Pennsylvania Hospital · 1 shared drug class
- University of Baghdad · 1 shared drug class
- VA Office of Research and Development · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for VA Greater Los Angeles Healthcare System:
- VA Greater Los Angeles Healthcare System pipeline updates — RSS
- VA Greater Los Angeles Healthcare System pipeline updates — Atom
- VA Greater Los Angeles Healthcare System pipeline updates — JSON
Cite this brief
Drug Landscape (2026). VA Greater Los Angeles Healthcare System — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/va-greater-los-angeles-healthcare-system. Accessed 2026-05-17.